Dynocardia, Inc.
Newton, MA
- UEI
- HMN7FWLXJ1H4
- CAGE
- 87W08
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 1188 Centre St #2, Newton Centre, MA 02459, USA
- Website
- dynocardia.care
- Founded
- 2018
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- SIC code
- 38 Instruments & Related Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Vena Vitals Inc. | Irvine, CA | 339112 Surgical and Medical Instrument Manufacturing |
| Kilele Health Inc. | Dayton, OH | — |
| Pyrames Inc. | Cupertino, CA | 339112 Surgical and Medical Instrument Manufacturing |
| Rhaeos, Inc. | Chicago, IL | — |
| Actiox LLC | Thousand Oaks, CA | — |
About the company
Dynocardia, Inc. is a for-profit corporate entity registered in SAM.gov, with its primary address located in Newton Centre, Massachusetts. The company focuses on developing advanced medical technology, specifically innovative wearable medical devices for continuous and non-invasive blood pressure monitoring. Their flagship product, Vitrack, is a wrist-wearable device that utilizes proprietary optomechanical sensor technology and computer vision algorithms to provide accurate, beat-to-beat blood pressure measurements across various clinical settings.
Through multiple federal grant awards, primarily from the National Science Foundation (NSF) and the National Heart, Lung, and Blood Institute (NHLBI), Dynocardia has been developing and refining its Vitrack device through Small Business Innovation Research (SBIR) Phase I and Phase II grants. These awards, totaling approximately $1.7 million, have supported the company's efforts to address critical challenges in blood pressure monitoring, such as motion artifact correction, continuous measurement in hospital intensive care and operating room settings, and specialized applications like monitoring hypertensive diseases during pregnancy. The grants have enabled Dynocardia to develop advanced computer vision algorithms, create synthetic training data, integrate artificial intelligence for motion correction, and conduct clinical validations of their technology. The ultimate goal of these projects is to create a production-ready device that can provide accurate, continuous blood pressure monitoring, potentially improving patient outcomes in hospitals, remote patient monitoring, and consumer wellness markets.
Quick answers
Is Dynocardia, Inc. registered in SAM.gov?
Yes. Dynocardia, Inc.'s SAM.gov registration is active through February 5, 2027.
What is Dynocardia, Inc.'s most recent federal award?
Dynocardia, Inc.'s most recent federal grant award is Sbir phase II: development of motion artifact correction systems for vitrack: an accurate, continuous, and non-invasive… (2423296), from National Science Foundation, on September 15, 2024.
On GovTribe
See Dynocardia, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors